# Examining the Merck Sharp & Dohme p53 peptidomimetic patent Landscape: A Personal Review
In the evolving field of peptide chemistry and molecular research, few areas command as much technical fascination as the developments surrounding the Merck Sharp & Dohme p53 peptidomimetic patent portfolio. As an enthusiast who keeps a close eye on library filings and intellectual property trends, I have spent significant time analyzing the documentation provided by organizations like WIPO and the USPTO. This deep dive focuses on the structural innovations detailed in these filings, particularly regarding complex macrocyclic designs.
When revi These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation … ewing the technical specifications within these patents, such as *US20250042961A1* or the *WO/2020/257153* filings, the focus shifts to the physical architecture of the molecules. The LSI terms often ass U.S. Patent Application for P53 PEPTIDOMIMETIC MACROCYCLES Patent ociated with this research include "protease-resistant" and "all-D configuration α-amino acids," which are critical f Disclosed are p53 peptidomimetic macrocycles, each p53 peptidomimetic macrocycle comprising an i, i+4 olefin staple and a … or enhancing the bio-stability of these compounds.
What fascinates me, as someone who follows peptide synthesis closely, is the integration of the i, i+4 olefin staple. This technique is a variation of peptide engineering that locks the molecule into an alpha-helical conformation. By stabilizing the secondary structure, these peptidomimetic macrocycles are able to mimic natural protein-protein interactions without the rapid degradation that usually plagues linear sequences. The p53 activator function—specifically aimed at the inhibition of MDM2 and MDMX (also known as MDM4)—is the primary target of this biological engineering.
Why This Research Is Notable
From a personal experience standpoint, tracking the evolution of Merck Sharp & Dohme (MSD) patents provides a window into the transition from traditional chemical compounds to specialized, high-affinity peptide derivatives. Many of these inventions are designed for those exploring the *mechanism of action* in laboratory This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the … settings.
The patent landscape, which covers everything from substituted piperidines to complex macrocycles, is incredibly vast. If you are eve These crosslinked peptidomimetic macrocycles have improved binding to MDM2 and MDMX (aka MDM4), are protease resistant, … r searching for a p53 inhibitor (Astex Pharmaceuticals/MSD) update, you will notice that the consistency of these patents shows a move toward higher cell permeability without membrane disruption. This is a crucial detail for anyone monitoring *SAR (Structure-Activity Relationship)* studies.
Addressing the Search Intent
* Patent search efficacy: When navigating these databases, it is vital to know that simply querying a company name isn't enough; filtering by specific titles like "P53 activator peptidomimetic macrocycles" yields more accurate results.
* Defining the scope: Many users are often confused about the difference between a standard peptide and a peptidomimetic. In my view, the distinction lies in the deliberate modification of the peptide backbone, which allows non-natural configurations to persist in challenging environments.
* Technological roadmap: By reviewing assignments to entities like Merck Sharp & Dohme LLC, we gain insight into the *priority date* an U.S. Patent Application for C-TERMINAL EXTENDED P53 … d the developmental trajectory of these proprietary molecular architectures.
Concluding Thoughts on the Landscape
The rigor applied to these patents—especially those detailing C-terminal extended p53 derivatives—demonstrates a high standard for intellectual property protection in biochemistry. The shift toward protease-resistant frameworks represents a massive leap forward in ensuring that modular chemical tools retain their integrity during research cycles.
For any researcher or enthusiast keeping tr WO/2023/107353 P53 PEPTIDOMIMETIC MACROCYCLES - WIPO ack of these advancements, the provided technical documentation on sites like *Google Patents* serves as a primary source of truth. As U.S. Patent Application for C-TERMINAL EXTENDED P53 … we look ahead, the persistent development around these p53-directed peptidomimetic macrocycles will likely remain a pillar of research interest, provided we continue to focus on the granular data points that define their structural efficacy. Always rely on primary documentation when evaluating the specific design claims of these molecules, as the nuances found in the patent abstracts are where the true industry insight is hidden.
# Examining the Merck Sharp & Dohme p53 peptidomimetic patent Landscape: A Personal Review
In the evolving field of peptide chemistry and molecular research, few areas command as much technical fascination as the developments surrounding the Merck Sharp & Dohme p53 peptidomimetic patent portfolio. As an enthusiast who keeps a close eye on library filings and intellectual property trends, I have spent significant time analyzing the documentation provided by organizations like WIPO and the USPTO. This deep dive focuses on the structural innovations detailed in these filings, particularly regarding complex macrocyclic designs.
When revi These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation … ewing the technical specifications within these patents, such as *US20250042961A1* or the *WO/2020/257153* filings, the focus shifts to the physical architecture of the molecules. The LSI terms often ass U.S. Patent Application for P53 PEPTIDOMIMETIC MACROCYCLES Patent ociated with this research include "protease-resistant" and "all-D configuration α-amino acids," which are critical f Disclosed are p53 peptidomimetic macrocycles, each p53 peptidomimetic macrocycle comprising an i, i+4 olefin staple and a … or enhancing the bio-stability of these compounds.
What fascinates me, as someone who follows peptide synthesis closely, is the integration of the i, i+4 olefin staple. This technique is a variation of peptide engineering that locks the molecule into an alpha-helical conformation. By stabilizing the secondary structure, these peptidomimetic macrocycles are able to mimic natural protein-protein interactions without the rapid degradation that usually plagues linear sequences. The p53 activator function—specifically aimed at the inhibition of MDM2 and MDMX (also known as MDM4)—is the primary target of this biological engineering.
Why This Research Is Notable
From a personal experience standpoint, tracking the evolution of Merck Sharp & Dohme (MSD) patents provides a window into the transition from traditional chemical compounds to specialized, high-affinity peptide derivatives. Many of these inventions are designed for those exploring the *mechanism of action* in laboratory This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the … settings.
The patent landscape, which covers everything from substituted piperidines to complex macrocycles, is incredibly vast. If you are eve These crosslinked peptidomimetic macrocycles have improved binding to MDM2 and MDMX (aka MDM4), are protease resistant, … r searching for a p53 inhibitor (Astex Pharmaceuticals/MSD) update, you will notice that the consistency of these patents shows a move toward higher cell permeability without membrane disruption. This is a crucial detail for anyone monitoring *SAR (Structure-Activity Relationship)* studies.
Addressing the Search Intent
* Patent search efficacy: When navigating these databases, it is vital to know that simply querying a company name isn't enough; filtering by specific titles like "P53 activator peptidomimetic macrocycles" yields more accurate results.
* Defining the scope: Many users are often confused about the difference between a standard peptide and a peptidomimetic. In my view, the distinction lies in the deliberate modification of the peptide backbone, which allows non-natural configurations to persist in challenging environments.
* Technological roadmap: By reviewing assignments to entities like Merck Sharp & Dohme LLC, we gain insight into the *priority date* an U.S. Patent Application for C-TERMINAL EXTENDED P53 … d the developmental trajectory of these proprietary molecular architectures.
Concluding Thoughts on the Landscape
The rigor applied to these patents—especially those detailing C-terminal extended p53 derivatives—demonstrates a high standard for intellectual property protection in biochemistry. The shift toward protease-resistant frameworks represents a massive leap forward in ensuring that modular chemical tools retain their integrity during research cycles.
For any researcher or enthusiast keeping tr WO/2023/107353 P53 PEPTIDOMIMETIC MACROCYCLES - WIPO ack of these advancements, the provided technical documentation on sites like *Google Patents* serves as a primary source of truth. As U.S. Patent Application for C-TERMINAL EXTENDED P53 … we look ahead, the persistent development around these p53-directed peptidomimetic macrocycles will likely remain a pillar of research interest, provided we continue to focus on the granular data points that define their structural efficacy. Always rely on primary documentation when evaluating the specific design claims of these molecules, as the nuances found in the patent abstracts are where the true industry insight is hidden.